BRPI0417213A - tratamento de gliomas malìgnos com inibidores de tgf-beta - Google Patents

tratamento de gliomas malìgnos com inibidores de tgf-beta

Info

Publication number
BRPI0417213A
BRPI0417213A BRPI0417213-2A BRPI0417213A BRPI0417213A BR PI0417213 A BRPI0417213 A BR PI0417213A BR PI0417213 A BRPI0417213 A BR PI0417213A BR PI0417213 A BRPI0417213 A BR PI0417213A
Authority
BR
Brazil
Prior art keywords
tgf
beta
inhibitors
treatment
malignant gliomas
Prior art date
Application number
BRPI0417213-2A
Other languages
English (en)
Inventor
Michael Weller
Sundeep Dugar
Linda S Higgins
David Y Liu
George F Schreiner
Sarvajit Chakravarty
Original Assignee
Scios Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Scios Inc filed Critical Scios Inc
Publication of BRPI0417213A publication Critical patent/BRPI0417213A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

"TRATAMENTO DE GLIOMAS MALìGNOS COM INIBIDORES DE TGF-BETA". A presente invenção refere-se a métodos de tratamento de gliomas malígnos, por administração de inibidores de TGF-beta, a TGF-beta sinalizando trajetória, incluindo moléculas de preferência ligando-se ao receptor de TGF-bera de tipo 1 (TGFbeta-R1). De preferência, os inibidores são moléculas pequenas de não peptídeo, incluindo derivados de quinazolina. A invenção também refere-se a métodos para a reversão do efeito mediado de TGF-beta sobre células de glioma para torná-las menos refráteis a sinalização e a outras células imunes, compreendendo o contato de um tecido ou célula de glioma in vivo ou in vitro, com um inibidor de TGF-beta.
BRPI0417213-2A 2003-12-24 2004-12-22 tratamento de gliomas malìgnos com inibidores de tgf-beta BRPI0417213A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US53234603P 2003-12-24 2003-12-24
PCT/US2004/043503 WO2005065691A1 (en) 2003-12-24 2004-12-22 Treatment of malignant gliomas with tgf-beta inhibitors

Publications (1)

Publication Number Publication Date
BRPI0417213A true BRPI0417213A (pt) 2007-02-06

Family

ID=34748794

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0417213-2A BRPI0417213A (pt) 2003-12-24 2004-12-22 tratamento de gliomas malìgnos com inibidores de tgf-beta

Country Status (11)

Country Link
US (1) US20050245508A1 (pt)
EP (1) EP1708712A1 (pt)
JP (1) JP2007517046A (pt)
KR (1) KR20070007055A (pt)
CN (1) CN1921864A (pt)
AU (1) AU2004312049A1 (pt)
BR (1) BRPI0417213A (pt)
CA (1) CA2551524A1 (pt)
MX (1) MXPA06008157A (pt)
RU (1) RU2006122519A (pt)
WO (1) WO2005065691A1 (pt)

Families Citing this family (62)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2006524633A (ja) * 2002-11-22 2006-11-02 サイオス・インコーポレーテツド β−アドレナリン作動性経路における病理学的変化を打ち消すための方法
JP2008543888A (ja) 2005-06-24 2008-12-04 ギリアード サイエンシーズ， インコーポレイテッド ピリド（３，２−ｄ）ピリミジン、およびＣ型肝炎を治療するのに有用な医薬組成物
US8338435B2 (en) 2006-07-20 2012-12-25 Gilead Sciences, Inc. Substituted pyrido(3,2-D) pyrimidines and pharmaceutical compositions for treating viral infections
EP2918288B1 (en) 2006-10-03 2017-08-16 Genzyme Corporation Use of TGF beta antagonists to treat infants at risk of developing bronchopulmonary dysplasia
TW200840584A (en) 2006-12-26 2008-10-16 Gilead Sciences Inc Pyrido(3,2-d)pyrimidines useful for treating viral infections
WO2008110891A2 (en) * 2007-03-09 2008-09-18 Orchid Research Laboratories Limited, New heterocyclic compounds
WO2010002998A1 (en) 2008-07-03 2010-01-07 Gilead Sciences, Inc. 2,4,6-TRISUBSTITUTED PYRIDO (3,2-d) PYRIMIDINES USEFUL FOR TREATING VIRAL INFECTIONS
EP2397157A4 (en) * 2009-02-11 2013-05-01 Univ Tokyo PROMOTER FOR BRAIN TUMOR STEM CELL DIFFERENTIATION AND THERAPEUTIC FOR BRAIN TUMOR
ES2740424T3 (es) 2009-03-13 2020-02-05 Agios Pharmaceuticals Inc Métodos y composiciones para trastornos relacionados con la proliferación celular
SG10201403696UA (en) 2009-06-29 2014-10-30 Agios Pharmaceuticals Inc Therapeutic compounds and compositions
EP3064595B1 (en) 2009-10-21 2019-02-27 Agios Pharmaceuticals, Inc. Methods for cell-proliferation-related disorders
EP2515916B1 (en) 2009-12-23 2016-03-09 Gradalis, Inc. Furin-knockdown and gm-csf-augmented (fang) cancer vaccine
US9157084B2 (en) 2009-12-23 2015-10-13 Gradalis, Inc. Furin-knockdown bi-functional RNA
US8815893B2 (en) * 2010-02-22 2014-08-26 Merck Patent Gmbh Hetarylaminonaphthyridines
CN102958930B (zh) 2010-06-28 2018-04-27 默克专利有限公司 作为用于对抗癌症的激酶抑制剂的2,4-二芳基取代的[1,8]二氮杂萘化合物
US9051318B2 (en) 2011-03-09 2015-06-09 Merck Patent Gmbh Pyrido [2, 3-B] pyrazine compounds and their therapeutical uses such as for inhibiting ATP consuming proteins and treating diseases associated therewith
JP6272754B2 (ja) 2011-05-03 2018-01-31 アジオス ファーマシューティカルズ， インコーポレイテッド ピルビン酸キナーゼ活性化剤の使用方法
CN102827170A (zh) 2011-06-17 2012-12-19 安吉奥斯医药品有限公司 治疗活性组合物和它们的使用方法
CN102827073A (zh) 2011-06-17 2012-12-19 安吉奥斯医药品有限公司 治疗活性组合物和它们的使用方法
BR112014009789A2 (pt) 2011-10-26 2017-04-25 Seattle Children's Res Inst cisteamina no tratamento da doença fibrótica
LT2800743T (lt) 2012-01-06 2018-06-25 Agios Pharmaceuticals, Inc. Terapiškai aktyvūs junginiai ir jų panaudojimo būdai
US9474779B2 (en) 2012-01-19 2016-10-25 Agios Pharmaceuticals, Inc. Therapeutically active compositions and their methods of use
MX385227B (es) 2012-01-20 2025-03-14 Del Mar Pharmaceuticals Uso de hexitoles sustituidos que incluyen dianhidrogalactitol y análogos para tratar enfermedad neoplásica y células madre de cáncer que incluyen glioblastoma multiforme y meduloblastoma.
US9145411B2 (en) 2012-08-02 2015-09-29 Asana Biosciences, Llc Substituted amino-pyrimidine derivatives
NZ706999A (en) 2012-10-15 2018-12-21 Agios Pharmaceuticals Inc Inhibitors of mutant isocitrate dehydrogenase and therapeutical uses thereof
DK2970890T3 (da) 2013-03-14 2020-05-04 Brigham & Womens Hospital Inc Sammensætninger og fremgangsmåder til opformering og dyrkning af epitelstamceller
ES2807582T3 (es) 2013-07-11 2021-02-23 Agios Pharmaceuticals Inc Compuestos N,6-bis(aril o heteroaril)-1,3,5-triazina-2,4-diamina como inhibidores de mutantes IDH2 para el tratamiento del cáncer
WO2015003360A2 (en) 2013-07-11 2015-01-15 Agios Pharmaceuticals, Inc. Therapeutically active compounds and their methods of use
US10376510B2 (en) 2013-07-11 2019-08-13 Agios Pharmaceuticals, Inc. 2,4- or 4,6-diaminopyrimidine compounds as IDH2 mutants inhibitors for the treatment of cancer
WO2015003355A2 (en) 2013-07-11 2015-01-15 Agios Pharmaceuticals, Inc. Therapeutically active compounds and their methods of use
WO2015010297A1 (en) 2013-07-25 2015-01-29 Agios Pharmaceuticals, Inc. Therapeutically active compounds and their methods of use
CN109045032A (zh) * 2014-01-01 2018-12-21 麦迪威森技术有限责任公司 氨基吡啶类化合物和使用方法
EP3105246B1 (en) * 2014-02-10 2021-03-31 Merck Patent GmbH Targeted tgf beta inhibition
US9968595B2 (en) 2014-03-14 2018-05-15 Agios Pharmaceuticals, Inc. Pharmaceutical compositions of therapeutically active compounds
JP2017522555A (ja) * 2014-06-26 2017-08-10 インスティテュート フォー システムズ バイオロジーＩｎｓｔｉｔｕｔｅ Ｆｏｒ Ｓｙｓｔｅｍｓ Ｂｉｏｌｏｇｙ 多形膠芽腫（ｇｂｍ）のためのマーカー及び治療指標
WO2016037016A1 (en) 2014-09-03 2016-03-10 The Brigham And Women's Hospital, Inc. Compositions, systems, and methods for generating inner ear hair cells for treatment of hearing loss
US11021468B2 (en) 2015-04-01 2021-06-01 Rigel Pharmaceuticals, Inc. TGF-ß inhibitors
RS64777B1 (sr) 2015-06-11 2023-11-30 Agios Pharmaceuticals Inc Postupci upotrebe aktivatora piruvat kinaze
UA123401C2 (uk) 2015-10-15 2021-03-31 Аджиос Фармасьютікалз, Інк. Комбінована терапія для лікування злоякісних пухлин
DK3362066T3 (da) 2015-10-15 2021-11-22 Les Laboratoires Servier Sas Kombinationsterapi til behandling af maligniteter
JP2019506153A (ja) 2016-01-08 2019-03-07 マサチューセッツ インスティテュート オブ テクノロジー 分化した腸内分泌細胞およびインスリン産生細胞の作製
US10213511B2 (en) 2016-03-02 2019-02-26 Frequency Therapeutics, Inc. Thermoreversible compositions for administration of therapeutic agents
US11260130B2 (en) 2016-03-02 2022-03-01 Frequency Therapeutics, Inc. Solubilized compositions for controlled proliferation of stem cells / generating inner ear hair cells using a GSK3 inhibitor: IV
US10201540B2 (en) 2016-03-02 2019-02-12 Frequency Therapeutics, Inc. Solubilized compositions for controlled proliferation of stem cells / generating inner ear hair cells using GSK3 inhibitors: I
CN106243012A (zh) * 2016-08-02 2016-12-21 北方民族大学 新型吲哚类衍生物及其制备方法
MX390321B (es) 2016-12-30 2025-03-20 Frequency Therapeutics Inc Compuestos de 1h-pirrol-2,5-diona y metodos de uso de los mismos para inducir la auto-renovacion de celulas madre/progenitoras de soporte.
CN109420170B (zh) * 2017-08-25 2021-03-02 中国科学院上海营养与健康研究所 肿瘤微环境相关靶点tak1及其在抑制肿瘤中的应用
US10342786B2 (en) 2017-10-05 2019-07-09 Fulcrum Therapeutics, Inc. P38 kinase inhibitors reduce DUX4 and downstream gene expression for the treatment of FSHD
WO2019071144A1 (en) 2017-10-05 2019-04-11 Fulcrum Therapeutics, Inc. USE OF P38 INHIBITORS TO REDUCE DUX4 EXPRESSION
AU2019240065A1 (en) 2018-03-20 2020-09-24 Icahn School Of Medicine At Mount Sinai Kinase inhibitor compounds and compositions and methods of use
US10980788B2 (en) 2018-06-08 2021-04-20 Agios Pharmaceuticals, Inc. Therapy for treating malignancies
CN108912060B (zh) * 2018-06-14 2021-03-19 温州医科大学 一种喹唑啉类抗炎化合物及其合成方法
CN109053597B (zh) * 2018-06-14 2021-03-19 温州医科大学附属第二医院、温州医科大学附属育英儿童医院 一种炎症抑制化合物及其制备方法
CN108727282B (zh) * 2018-06-14 2021-03-02 温州医科大学附属第一医院 一种含苯磺酰氨基的抗炎化合物及其合成方法
CN108727283B (zh) * 2018-06-14 2021-03-02 温州医科大学附属第一医院 一种苯磺酰氨类抗炎化合物的合成方法
CN108912061B (zh) * 2018-06-14 2021-03-19 温州医科大学 一种喹唑啉类炎症抑制化合物的合成方法
CN108912059B (zh) * 2018-06-14 2021-03-02 温州医科大学附属第一医院 一种含氮杂环炎症抑制化合物的合成方法
JP2021533788A (ja) 2018-08-17 2021-12-09 フリークエンシー セラピューティクス インコーポレイテッド Ｊａｇ−１を上方制御することにより有毛細胞を生成するための組成物及び方法
WO2020037326A1 (en) 2018-08-17 2020-02-20 Frequency Therapeutics, Inc. Compositions and methods for generating hair cells by downregulating foxo
CA3124700A1 (en) 2018-12-31 2020-07-09 Icahn School Of Medicine At Mount Sinai Kinase inhibitor compounds and compositions and methods of use
US20220177978A1 (en) 2019-04-02 2022-06-09 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods of predicting and preventing cancer in patients having premalignant lesions
DK4426434T3 (da) 2021-11-02 2025-11-10 Flare Therapeutics Inc Pparg inverse agonists and uses thereof

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6455689B1 (en) * 1993-04-30 2002-09-24 Biognostik Gesellschaft für Biomolekulare Diagnostik mbH Antisense-oligonucleotides for transforming growth factor-β (TGF-β)
AU701623B2 (en) * 1993-10-14 1999-02-04 President And Fellows Of Harvard College Method of inducing and maintaining neuronal cells
US6184226B1 (en) * 1998-08-28 2001-02-06 Scios Inc. Quinazoline derivatives as inhibitors of P-38 α
IL161908A0 (en) * 2001-12-12 2005-11-20 Pfizer Prod Inc Quinazoline derivatives for the treatment of abnormal cell growth
AR039241A1 (es) * 2002-04-04 2005-02-16 Biogen Inc Heteroarilos trisustituidos y metodos para su produccion y uso de los mismos
WO2003097615A1 (en) * 2002-05-17 2003-11-27 Scios, Inc. TREATMENT OF FIBROPROLIFERATIVE DISORDERS USING TGF-β INHIBITORS
CA2520465A1 (en) * 2003-03-28 2004-10-14 Scios Inc. Bi-cyclic pyrimidine inhibitors of tgf.beta.
US7232824B2 (en) * 2003-09-30 2007-06-19 Scios, Inc. Quinazoline derivatives as medicaments

Also Published As

Publication number Publication date
CA2551524A1 (en) 2005-07-21
KR20070007055A (ko) 2007-01-12
EP1708712A1 (en) 2006-10-11
JP2007517046A (ja) 2007-06-28
RU2006122519A (ru) 2008-01-27
CN1921864A (zh) 2007-02-28
AU2004312049A1 (en) 2005-07-21
US20050245508A1 (en) 2005-11-03
WO2005065691A1 (en) 2005-07-21
MXPA06008157A (es) 2007-09-07

Similar Documents

Publication Publication Date Title
BRPI0510475B8 (pt) adenovírus quimérico recombinante, uso do mesmo no tratamento de câncer e métodos de inibição de crescimento de uma célula de câncer, de fornecimento de uma proteína terapêutica a uma célula e para o isolamento do adenovírus
NZ593289A (en) Anti-neuropilin-1 antibodies for treating angiogenesis
NZ704295A (en) Compositions and methods for the treatment of infections and tumors
ATE531729T1 (de) Kdr-peptide und diese enthaltende impfstoffe
BR0306993A (pt) Polìmero de polialquilenoglicol ativado; composição farmacêutica; método para tratar um paciente que tem uma infecção viral suscetìvel; e método para tratar um paciente suspeito de ter infecção por hepatite c
WO2003000928A3 (en) Methods for identification of cancer cell surface molecules and cancer specific promoters, and therapeutic uses thereof
BRPI0508931A (pt) ácido nucleico isolado, composição farmacêutica e usos de uma quantidade eficaz de um primeiro ligante de ácido nucleico
EP1140840A4 (en) -G (V) -CARBOXYARYL SUBSTITUTED DIPHENYL UREASINE AS RAF KINASE INHIBITORS
TR201903587T4 (tr) Telomeraz aktivitesinin artırılması için bileşimler.
WO2003004989A3 (en) Compositions, kits, and methods for identification, assessment, prevention, and therapy of breast cancer
BRPI0408247A (pt) usos de antagonistas e agonistas de il-23 e reagentes relacionados
WO2004113571A3 (en) Prostate specific genes and the use thereof as targets for prostate cancer therapy and diagnosis
WO2002101075A9 (en) Novel genes, compositions, kits, and methods for identification, assessment, prevention, and therapy of cervical cancer
ATE442142T1 (de) Fredericamycin-derivate als arzneimittel zur tumorbehandlung
BR9913532A (pt) Novos inibidores heteroaromáticos de frutose 1,6-bifosfatase
EP1931806A4 (en) PKR ACTIVATION BY HYBRIDIZATION CHAIN REACTION
BRPI0515577A (pt) compostos de carbonila que podem ser empregados como inibidores de fator xa de coagulação
TR200103560T2 (tr) Göğüs kanserinin teşhis ve tedavisi için bileşimler ve bunların kullanımı
WO2006124892A3 (en) Modulators of alpha-synuclein toxicity
WO2004106495A3 (en) Compositions, kits, and methods for identification, assessment, prevention, and therapy of breast cancer
BRPI0514295A (pt) 1, 5-difenilpirazóis
EA200800011A1 (ru) Тиенопиримидиновые и тиенопиридиновые модуляторы киназы
WO2003066663A3 (en) Peptides for recognition and targeting of glial cell tumors
DE502007005636D1 (de) Triaza-benzoäeüazulenderivate zur behandlung von tumoren
WO2008091873A3 (en) Compositions and methods for the identification, assessment, prevention and therapy of thymic lymphoma or hamartomatous tumours

Legal Events

Date Code Title Description
B11A Dismissal acc. art.33 of ipl - examination not requested within 36 months of filing
B11Y Definitive dismissal - extension of time limit for request of examination expired [chapter 11.1.1 patent gazette]